Seebri Neohaler launches in the US
Seebri Neohaler (Photo: Business Wire).
Company eligible to receive royalties from Novartis on net sales of the product.
Vectura Group has confirmed that Sunovion Pharmaceuticals, the US licensee of the Group's partner Novartis, has launched the twice-daily long acting muscarinic inhibitor (LAMA) Seebri Neohaler (glycopyrrolate 15.6 mcg), in the US.
Sunovion entered into an exclusive license agreement with Novartis for the US commercialisation rights to three of Novartis' COPD treatments, including Seebri Neohaler and Utibron Neohaler, on 21 December 2016 and in April 2017 Sunovion confirmed it had launched the dual long acting bronchodilator and muscarinic combination therapy (LABA-LAMA) Utibron Neohaler, in the US.
Vectura is eligible to receive royalties from Novartis on net sales of the product as well as certain milestones based on global calendar year combined net sales of Utibron Neohaler, Seebri Neohaler, Ultibro Breezhaler and Seebri Breezhaler. The royalties earned upon net sales of Seebri Neohaler are the same as those for Seebri Breezhaler.
James Ward-Lilley, CEO of Vectura: "Following the launch of Utibron in April we are pleased with the confirmation of launch of Seebri in the US. Whilst the commercial priority for 2017 has been securing market access and product listings we remain confident that Sunovion will be effective in the commercialisation of these products given its strong US respiratory track record and look forward to this being reflected in strong revenue growth in the US for these two products."
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
.png)
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
.png)
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
.png)
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
.png)
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance